 Connection
Michael Bristow to Cyclophosphamide
This is a "connection" page, showing publications Michael Bristow has written about Cyclophosphamide.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.115 |
|
|
|
-
Wagoner LE, Taylor DO, Olsen SL, Bristow MR, O'Connell JB, Hammond EH, Lappe DL, Renlund DG. Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review. Clin Transplant. 1996 Oct; 10(5):437-43.
Score: 0.032
-
Taylor DO, Bristow MR, O'Connell JB, Ensley RD, Olsen SL, Hammond EH, Wagoner LE, Renlund DG. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation. Decreased sensitization to OKT3. Transplantation. 1994 Sep 27; 58(6):645-9.
Score: 0.028
-
Wagoner LE, Olsen SL, Bristow MR, O'Connell JB, Taylor DO, Lappe DL, Renlund DG. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity. Transplantation. 1993 Dec; 56(6):1415-8.
Score: 0.026
-
Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med. 1986 Mar; 80(3):483-5.
Score: 0.015
-
Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis. 1984 Nov-Dec; 27(3):195-200.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|